SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001664710-21-000025
Filing Date
2021-05-06
Accepted
2021-05-06 16:07:45
Documents
59
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q kros-20210331.htm   iXBRL 10-Q 1216059
2 EX-31.1 exhibit311q12021.htm EX-31.1 16419
3 EX-31.2 exhibit312q12021.htm EX-31.2 16300
4 EX-32.1 exhibit321q12021.htm EX-32.1 9939
  Complete submission text file 0001664710-21-000025.txt   4441469

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kros-20210331.xsd EX-101.SCH 29858
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT kros-20210331_cal.xml EX-101.CAL 55346
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT kros-20210331_def.xml EX-101.DEF 141919
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kros-20210331_lab.xml EX-101.LAB 394585
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kros-20210331_pre.xml EX-101.PRE 267502
10 EXTRACTED XBRL INSTANCE DOCUMENT kros-20210331_htm.xml XML 499758
Mailing Address 99 HAYDEN AVENUE, SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER LEXINGTON MA 02421
Business Address 99 HAYDEN AVENUE, SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER LEXINGTON MA 02421 617-513-8774
Keros Therapeutics, Inc. (Filer) CIK: 0001664710 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39264 | Film No.: 21897757
SIC: 2834 Pharmaceutical Preparations